An ongoing, multisite study, LEADER, evaluated lecanemab in clinical settings, incorporating data from 432 patients with early Alzheimer’s disease. Participants received at least seven biweekly lecanemab infusions, with some receiving IV or subcutaneous maintenance treatment after 18 months. The median time on lecanemab was 520.7 days, and patients received an average of 25.8 doses. The study includes diverse real-world settings, featuring general neurologists not involved in the CLARITY AD trial. Close prescriber-radiologist collaboration was key to the study’s success, ensuring clear communication regarding ARIA detection and management. ARIA, a consequence of amyloid in blood vessel walls, can manifest as ARIA with edema or effusion (ARIA-E) or ARIA with hemosiderin or hemorrhage (ARIA-H). The LEADER study’s ARIA rates were consistent with those seen in clinical trials. Any ARIA occurred in 12.3% of patients, compared to 21.3% in the CLARITY AD trial. ARIA-E occurred in 6.5% of patients versus 12.6%, and ARIA-H in 7.6% versus 17.3%. Concurrent ARIA-E and ARIA-H occurred in 1.9% versus 8.2% of patients. The median time to ARIA-E was 3.4 months, and results were similar between 1.5T and 3T MRI. Lecanemab, an antibody targeting amyloid beta, was approved in 2023 for mild cognitive impairment and mild Alzheimer’s dementia. The drug carries a boxed warning regarding potential ARIA-E or ARIA-H occurrences, with a higher incidence observed in individuals who are APOE4 homozygotes. ARIA is often asymptomatic, and monitoring via MRI at baseline, then after 1, 2, 3, and 6 months of treatment is required. The LEADER study has expanded to 20 sites and now incorporates subcutaneous administration, which the FDA approved earlier this year.